嗜酸乳杆菌
胃肠病学
体内
内科学
肾脏疾病
血液透析
内分泌学
医学
化学
生物
益生菌
细菌
生物技术
遗传学
作者
Michael L. Simenhoff,Stephen Dunn,G P Zollner,ME Fitzpatrick,S M Emery,W. E. Sandine,James W. Ayres
出处
期刊:PubMed
日期:1996-01-01
卷期号:22 (1-3): 92-6
被引量:136
摘要
Small bowel bacterial overgrowth (SBBO), well known to occur in end-stage kidney failure, is responsible for producing uremic toxins and contributing to the patient's decreased nutritional well-being. In this study, 8 hemodialysis patients were treated with a course of oral Lactobacillus acidophilus (LBA) in an attempt to alter this SBBO. LBA treatment was effective in lowering 2 compounds generated in vivo. Serum dimethylamine (DMA) levels dropped from 224 +/- 47 to 154 +/- 47 micrograms/dl at the end of LBA treatment (p < 0.001). Nitrosodimethylamine, a carcinogen, levels also decreased significantly from 178 +/- 67 (untreated) to 83 +/- 49 ng/kg (after LBA treatment). Patients nutritional status, assessed as serum albumin, body weight, caloric intake, midarm muscle area (MAMA) and appetite improved modestly, but not significantly. LBA changed small bowel pathobiology by modifying metabolic actions of SBBO, reducing in vivo generation of toxins and carcinogens and promoting nutrition with no adverse side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI